Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model

Monteiro,Robson   Q.; Lima,Luize G.; Gonçalves,Nathália   P.; De Souza,Mayara  R. Arruda; Leal,Ana  C.; Demasi,Marcos  A. Almeida; Sogayar,Mari  C.; Carneiro‑Lobo,Tatiana  C.

doi:10.3892/ol.2016.4593

Hypoxia regulates the expression of tissue factor pathway signaling elements in a rat glioma model

Authors:
- Robson Q. Monteiro
- Luize G. Lima
- Nathália P. Gonçalves
- Mayara R. Arruda De Souza
- Ana C. Leal
- Marcos A. Almeida Demasi
- Mari C. Sogayar
- Tatiana C. Carneiro‑Lobo
View Affiliations

Affiliations: Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro, RJ 21941‑902, Brazil, Cell and Molecular Therapy Center (NUCEL‑NETCEM), Internal Medicine Department, School of Medicine, University of São Paulo, São Paulo, SP 05360‑120, Brazil
Published online on: May 17, 2016 https://doi.org/10.3892/ol.2016.4593
Pages: 315-322

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypoxia and necrosis are fundamental features of glioma, and their emergence is critical for the rapid biological progression of this fatal tumor. The presence of vaso‑occlusive thrombus is higher in grade IV tumors [glioblastoma multiforme (GBM)] compared with lower grade tumors, suggesting that the procoagulant properties of the tumor contribute to its aggressive behavior, as well as the establishment of tumor hypoxia and necrosis. Tissue factor (TF), the primary cellular initiator of coagulation, is overexpressed in GBMs and likely favors a thrombotic microenvironment. Phosphatase and tensin homolog (PTEN) loss and hypoxia are two common alterations observed in glioma that may be responsible for TF upregulation. In the present study, ST1 and P7 rat glioma lines, with different levels of aggressiveness, were comparatively analyzed with the aim of identifying differences in procoagulant mechanisms. The results indicated that P7 cells display potent procoagulant activity compared with ST1 cells. Flow cytometric analysis showed less pronounced levels of TF in ST1 cells compared with P7 cells. Notably, P7 cells supported factor X (FX) activation via factor VIIa, whereas no significant FXa generation was observed in ST1 cells. Furthermore, the exposure of phosphatidylserine on the surface of P7 and ST1 cells was investigated. The results supported the assembly of prothrombinase complexes, accounting for the production of thrombin. Furthermore, reverse transcription‑quantitative polymerase chain reaction showed that CoCl2 (known to induce a hypoxic‑like stress) led to an upregulation of TF levels in P7 and ST1 cells. Therefore, increased TF expression in P7 cells was accompanied by increased TF procoagulant activity. In addition, hypoxia increased the shedding of procoagulant TF‑bearing microvesicles in both cell lines. Finally, hypoxic stress induced by treatment with CoCl2 upregulated the expression of the PAR1 receptor in both P7 and ST1 cells. In addition to PAR1, P7, but not ST1 cells, expressed higher levels of PAR2 under hypoxic stress. Thus, modulating these molecular interactions may provide additional insights for the development of more efficient therapeutic strategies against aggressive glioma.

View Figures

View References

1	Williams JC and Mackman N: Tissue factor in health and disease. Front Biosci. 1:358–372. 2012. View Article : Google Scholar
2	Østerud B and Bjørklid E: Sources of tissue factor. Semin Thromb Hemost. 32:11–23. 2006. View Article : Google Scholar : PubMed/NCBI
3	Francischetti IM, Seydel KB and Monteiro RQ: Blood coagulation, inflammation, and malaria. Microcirculation. 15:81–107. 2008. View Article : Google Scholar : PubMed/NCBI
4	Brat DJ and Van Meir EG: Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma. Lab Invest. 84:397–405. 2004. View Article : Google Scholar : PubMed/NCBI
5	Rak J, Milsom C, Magnus N and Yu J: Tissue factor in tumour progression. Best Pract Res Clin Haematol. 22:71–83. 2009. View Article : Google Scholar : PubMed/NCBI
6	Kasthuri RS, Taubman MB and Mackman N: Role of tissue factor in cancer. J Clin Oncol. 27:4834–4838. 2009. View Article : Google Scholar : PubMed/NCBI
7	Ruf W, Disse J, Carneiro-Lobo TC, Yokota N and Schaffner F: Tissue factor and cell signalling in cancer progression and thrombosis. J Thromb Haemost. 9(Suppl 1): S306–S315. 2011. View Article : Google Scholar
8	van den Berg YW, Osanto S, Reitsma PH and Versteeg HH: The relationship between tissue factor and cancer progression: Insights from bench and bedside. Blood. 119:924–932. 2012. View Article : Google Scholar : PubMed/NCBI
9	Lima LG and Monteiro RQ: Activation of blood coagulation in cancer: Implications for tumour progression. Biosci Rep. 33:e000642013. View Article : Google Scholar : PubMed/NCBI
10	Lima LG, Oliveira AS, Campos LC, Bonamino M, Chammas R, Werneck C, Vicente CP, Barcinski MA, Petersen LC and Monteiro RQ: Malignant transformation in melanocytes is associated with increased production of procoagulant microvesicles. Thromb Haemost. 106:712–723. 2011. View Article : Google Scholar : PubMed/NCBI
11	Zhou L, Qi XL, Xu MX, Mao Y, Liu ML and Song HM: Microparticles: New light shed on the understanding of venous thromboembolism. Acta Pharmacol Sin. 35:1103–1110. 2014. View Article : Google Scholar : PubMed/NCBI
12	Boire A, Covic L, Agarwal A, Jacques S, Sherifi S and Kuliopulos A: PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell. 120:303–313. 2005. View Article : Google Scholar : PubMed/NCBI
13	Albrektsen T, Sørensen BB, Hjortø GM, Fleckner J, Rao LV and Petersen LC: Transcriptional program induced by factor VIIa-tissue factor, PAR1 and PAR2 in MDA-MB-231 cells. J Thromb Haemost. 5:1588–1597. 2007. View Article : Google Scholar : PubMed/NCBI
14	Wen PY and Kerasi S: Malignant gliomas in adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
15	Evans SM, Judy KD, Dunphy I, Jenkins WT, Nelson PT, Lustig RA, Jenkins K, Magarelli DP, Hahn SM, Collins RA, et al: Hypoxia is important in the biology and aggression of human glial brain tumors. Clin Cancer Res. 10:8177–8184. 2004. View Article : Google Scholar : PubMed/NCBI
16	Brown JM and Wilson WR: Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004. View Article : Google Scholar : PubMed/NCBI
17	Anand M and Brat DJ: Oncogenic regulation of tissue factor and thrombosis in cancer. Thromb Res. 129(Suppl 1): S46–S49. 2012. View Article : Google Scholar : PubMed/NCBI
18	Magnus N, D'Asti E, Meehan B, Garnier D and Rak J: Oncogenes and the coagulation system-forces that modulate dormant and aggressive states in cancer. Thromb Res. 133(Suppl 2): S1–S9. 2014. View Article : Google Scholar : PubMed/NCBI
19	Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG and Brat DJ: PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res. 65:1406–1413. 2005. View Article : Google Scholar : PubMed/NCBI
20	Magnus N, Garnier D and Rak J: Oncogenic epidermal growth factor receptor up-regulates multiple elements of the tissue factor signaling pathway in human glioma cells. Blood. 116:815–818. 2010. View Article : Google Scholar : PubMed/NCBI
21	D'Asti E, Fang Y and Rak J: Brain neoplasms and coagulation-lessons from heterogeneity. Rambam Maimonides Med J. 5:e00302014. View Article : Google Scholar : PubMed/NCBI
22	Carneiro-Lobo TC, Lima MT, Mariano-Oliveira A, Dutra-Oliveira A, Oba-Shinjo SM, Marie SK, Sogayar MC and Monteiro RQ: Expression of tissue factor signaling pathway elements correlates with the production of vascular endothelial growyh factor and interleukin-8 in human astrocytoma patients. Oncol Rep. 31:679–686. 2014.PubMed/NCBI
23	Armelin MC and Armelin HÀ: Glucocorticoid hormone modulation of both cell surface and cytoskeleton related to growth control of rat glioma cells. J Cell Biol. 97:459–465. 1983. View Article : Google Scholar : PubMed/NCBI
24	Armelin MC, Stocco RC and Armelin HA: Control of rat C6 glioma cell proliferation: Uncoupling of the inhibitory effects of hydrocortisone hormone in suspension and monolayer cultures. J Cell Biol. 97:455–458. 1983. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCt. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Hamada K, Kuratsu J, Saitoh Y, Takeshima H, Nishi T and Ushio Y: Expression of tissue factor correlates with grade of malignancy in human glioma. Cancer. 77:1877–1883. 1996. View Article : Google Scholar : PubMed/NCBI
27	Guan M, Jin J, Su B, Liu WW and Lu Y: Tissue factor expression and angiogenesis in human glioma. Clin Biochem. 35:321–325. 2002. View Article : Google Scholar : PubMed/NCBI
28	Fernandes RS, Kirszberg C, Rumjanek VM and Monteiro RQ: On the molecular mechanisms for the highly procoagulant pattern of C6 glioma cells. J Thromb Haemost. 4:1546–1552. 2006. View Article : Google Scholar : PubMed/NCBI
29	Kirszberg C, Lima LG, Da Silva de Oliveira A, Pickering W, Gray E, Barrowcliffe TW, Rumjanek VM and Monteiro RQ: Simultaneous tissue factor expression and phosphatidylserine exposure account for the highly procoagulant pattern of melanoma cell lines. Melanoma Res. 19:301–308. 2009. View Article : Google Scholar : PubMed/NCBI
30	Brat DJ, Castellano-Sanchez AA, Hunter SB, Pecot M, Cohen C, Hammond EH, Devi SN, Kaur B and Van Meir EG: Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases and are formed by an actively migrating cell population. Cancer Res. 64:920–927. 2004. View Article : Google Scholar : PubMed/NCBI
31	Rautou PE and Mackman N: Microvesicles as risk markers for venous thrombosis. Expert Rev Hematol. 6:91–101. 2013. View Article : Google Scholar : PubMed/NCBI
32	Svensson KJ, Kucharzewska P, Christianson HC, Sköld S, Löfstedt T, Johansson MC, Mörgelin M, Bengzon J, Ruf W and Belting M: Hypoxia triggers a proangiogenic pathway involving cancer cell microvesicles and PAR-2-mediated heparin-binding EGF signaling in endothelial cells. Proc Natl Acad Sci USA. 108:13147–13152. 2011. View Article : Google Scholar : PubMed/NCBI
33	Naldini A, Filippi I, Ardinghi C, Silini A, Giavazzi R and Carraro F: Identification of a functional role for the protease-activated receptor-1 in hypoxic breast cancer cells. Eur J Cancer. 45:454–460. 2009. View Article : Google Scholar : PubMed/NCBI
34	Hammoud MA, Sawaya R, Shi W, Thall PF and Leeds NE: Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neurooncol. 27:65–73. 1996. View Article : Google Scholar : PubMed/NCBI
35	Tehrani M, Friedman TM, Olson JJ and Brat DJ: Intravascular thrombosis in central nervous system malignancies: A potential role in astrocytoma progression to glioblastoma. Brain Pathol. 18:164–171. 2008. View Article : Google Scholar : PubMed/NCBI
36	Blanco VM, Chu Z, Vallabhapurapu SD, Sulaiman MK, Kendler A, Rixe O, Warnick RE, Franco RS and Qi X: Phosphatidylserine-selective targeting and anticancer effects of SapC-DOPS nanovesicles on brain tumors. Oncotarget. 5:7105–7118. 2014. View Article : Google Scholar : PubMed/NCBI
37	Wang T, Gilkes DM, Takano N, Xiang L, Luo W, Bishop CJ, Chaturvedi P, Green JJ and Semenza GL: Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc Natl Acad Sci USA. 111:E3234–E3242. 2014. View Article : Google Scholar : PubMed/NCBI
38	Marras LC, Geerts WH and Perry JR: The risk of venous thromboembolism is increased throughout the course of malignant glioma: An evidence-based review. Cancer. 89:640–664. 2000. View Article : Google Scholar : PubMed/NCBI
39	Thaler J, Ay C, Mackman N, Bertina RM, Kaider A, Marosi C, Key NS, Barcel DA, Scheithauer W, Kornek G, et al: Microparticle-associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 10:1363–1370. 2012. View Article : Google Scholar : PubMed/NCBI
40	Thaler J, Preusser M, Ay C, Kaider A, Marosi C, Zielinski C, Pabinger I and Hainfellner JA: Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 131:162–165. 2013. View Article : Google Scholar : PubMed/NCBI
41	Lima LG, Leal AC, Vargas G, Porto-Carreiro I and Monteiro RQ: Intercellular transfer of tissue factor via the uptake of tumor-derived microvesicles. Thromb Res. 132:450–456. 2013. View Article : Google Scholar : PubMed/NCBI
42	Zhang Y, Zhan H, Xu W, Yuan Z, Lu P, Zhan L and Li Q: Upregulation of matrix metalloproteinase-1 and proteinase-activated receptor-1 promotes the progression of human gliomas. Pathol Res Pract. 207:24–29. 2011. View Article : Google Scholar : PubMed/NCBI
43	Itsekson-Hayosh Z, Shavit-Stein E, Last D, Goez D, Daniels D, Bushi D, Gera O, Zibly Z, Mardor Y, Chapman J and Harnof S: Thrombin activity and thrombin receptor in rat glioblastoma model: Possible markers and targets for intervention? J Mol Neurosci. 56:644–651. 2015. View Article : Google Scholar : PubMed/NCBI
44	Dutra-Oliveira A, Monteiro RQ and Mariano-Oliveira A: Protease-activated receptor-2 (PAR2) mediates VEGF production through the ERK1/2 pathway in human glioblastoma cell lines. Biochem Biophys Res Commun. 421:221–227. 2012. View Article : Google Scholar : PubMed/NCBI
45	Harter PN, Dützmann S, Drott U, Zachskorn C, Hattingen E, Capper D, Gessler F, Senft C, Seifert V, Plate KH, et al: Anti-tissue factor (TF9-10H10) treatment reduces tumor cell invasiveness in a novel migratory glioma model. Neuropathology. 33:515–525. 2013.PubMed/NCBI
46	Luo R, Wang X, Dong Y, Wang L and Tian C: Activation of protease-activated receptor 2 reduces glioblastoma cell apoptosis. J Biomed Sci. 21:252014. View Article : Google Scholar : PubMed/NCBI
47	Carneiro-Lobo TC, Konig S, Machado DE, Nasciutti LE, Forni MF, Francischetti IM, Sogayar MC and Monteiro RQ: Ixolaris, a tissue factor inhibitor, blocks primary tumor growth and angiogenesis in a glioblastoma model. J Thromb Haemost. 7:1855–1864. 2009. View Article : Google Scholar : PubMed/NCBI
48	Carneiro-Lobo TC, Schaffner F, Disse J, Ostergaard H, Francischetti IM, Monteiro RQ and Ruf W: The tick-derived inhibitor Ixolaris prevents tissue factor signaling on tumor cells. J Thromb Haemost. 10:1849–1858. 2012. View Article : Google Scholar : PubMed/NCBI